Sysmex Inostics
Sysmex Inostics, Inc., a US-based Sysmex Corporation subsidiary, empowers discoveries in oncology by providing investigators with ultra-sensitive, and cost-effective CLIA-validated liquid biopsy services.
Developed by experts at Johns Hopkins, Sysmex Inostics’ Plasma-Safe-SeqS NGS technology has robust detection as low as 0.03% allele frequency (for input of 20,000 genomic equivalents) without sacrificing specificity.
In July 2021, Sysmex Corporation announced a strategic alliance with QIAGEN to expedite clinical trial timelines and CDx development.
Email questions to info@sysmex-inostics.com.